Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
10.5
Expiration
Dec 4, 2026
DTE
21d
Moneyness
OTM
Intrinsic
$0.00
IBRX 10.5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $0.20 | +0.00% | 45 | 109 |
| Nov 20, 2026 | 7d | $0.38 | -24.00% | 7 | 40 |
| Nov 27, 2026 | 14d | $0.40 | -28.57% | 105 | 578 |
| Dec 4, 2026 | 21d | — | — | 0 | 0 |
| Dec 11, 2026 | 28d | — | — | 0 | 0 |
| Dec 24, 2026 | 41d | — | — | 0 | 1 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
IBRX Nearby Strikes · Dec 4, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 7.5 C | $1.51 | -13.71% | 11 | 81 | OTM |
| 8 C | $1.47 | +13.08% | 4 | 16 | OTM |
| 8.5 C | $1.20 | +0.00% | 10 | 15 | OTM |
| 9 C | $1.63 | +61.39% | 1 | 1 | OTM |
| 9.5 C | $0.90 | +12.50% | 244 | 249 | OTM |
| 10 C | $0.95 | +35.71% | 1 | 360 | OTM |
| 10.5 C | — | — | 0 | 0 | OTM |
| 11 C | $0.50 | +2.04% | 90 | 484 | OTM |
| 11.5 C | — | — | 0 | 0 | OTM |
| 12 C | $0.36 | -26.53% | 3 | 244 | OTM |
| 12.5 C | $0.75 | +0.00% | 2 | 2 | OTM |
| 13 C | $0.35 | +0.00% | 5 | 4 | OTM |
| 13.5 C | $0.49 | +0.00% | 3 | 3 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.